Tonabersat by Inflammx Therapeutics for Wet (Neovascular / Exudative) Macular Degeneration: Likelihood of Approval
Pharmaceutical Technology
JANUARY 4, 2024
Tonabersat is under clinical development by Inflammx Therapeutics and currently in Phase II for Wet (Neovascular / Exudative) Macular Degeneration.
Let's personalize your content